

Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Program

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

September 21, 2011 Wednesday

08.30-09.00 Registration and Coffee

09.00-09.10 Welcome By Johan Hansson (Karolinska Institutet, Sweden)

Session 1: How to understand and to reverse drug resistance

Chair: Rolf Lewensohn (Karolinska Institutet, Sweden)

09.10-09.50 Parp Inhibitors sensitivity and resistance

By Thomas Helleday (University of Oxford, UK)

09.50-10.10 Functional genomic approaches to the dissection of drug resistance mechanisms in melanoma

By Suzanne Egyhazi (Karolinska Institutet, Sweden)

10.10-10.30 Functional genomic approaches to the dissection of drug resistance mechanisms in lung cancer

By Luigi De Petris (Karolinska Institutet, Sweden)

10.30-11.00 Coffee Break

11.00-11.40 Integration of system biology and bioinformatics in oncology

By Stephen H. Friend (Sage Bionetworks, USA)

11.45-13.00 Lunch



Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Program

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

September 21, 2011 Wednesday

Session 2: Towards the future: personalized medicine

Chair: Thomas Tursz (Institut Gustave Roussy, France)

13.00-13.30 Preliminary title: Overview and definition of biomarkers and predictive function

By Rolf Lewensohn (Karolinska Institutet, Sweden)

13.30-14.00 Is personalized medicine the future?

By Thomas Tursz (Institut Gustave Roussy, France)

14.00-14.30 How to personalize treatment in early lung cancer

By Benjamin Besse (Institut Gustave Roussy, France)

14.30-15.00 Limitations to individualized medicine

By Eytan Domany (Weizmann Institute of Science, Israel)

15.00-15.30 Coffee break

15.30-17.00 On-site seminars

Track I Clinical experiences: (Chair: Johan Hansson)

15.30-15.50 Patients sharing

15.50-16.05 Chemotherapy procedure

16.05-16.20 Case presentations by Luigi De Petris (KI, Sweden)

16.20-16.40 Case presentations by Gunnar Wagenius (Uppsala University, Sweden)

Track II Pre-clinical experiences: Life Science Lab

15.30-16.00 Janne Lehtiö (KI, Sweden)

16.00-16.30 Joakim Lundeberg (KTH, Sweden)

18.00

Dinner



Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Program

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

September 22, 2011 Thursday

Session 3: Melanoma therapy-realizing the potential in targeted therapy Chair: Johan Hansson (Karolinska Institutet, Sweden)

09.30-09.50 Coffee

09.50-10.30 **Recent advances in the treatment of advanced melanoma**
By Alexander M.M. Eggermont (Institut Gustave Roussy, France)

10.30-10.45 Coffee Break

10.45-11.20 **PLX 4032 and follow-up molecules**
By Mark Middleton (University of Oxford, UK)

11.20-11.55 **Role of pharmacokinetics in cancer chemotherapy**
By Curt Peterson (Linköping University, Sweden)

11.55-13.00 Lunch



Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Program

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

September 22, 2011 Thursday

Session 4: Current insights of biomarker assessment and clinical recommendations in lung cancer

13.00-13.30 Current status on lung cancer

By Rolf Stahel (University Hospital Zurich, Switzerland)

13.30-14.00 Novel targeted therapies for metastatic non-small cell lung cancer

By Rafal Dziadziuszko (Medical University of Gdansk, Poland)

14.00-14.30 Coffee break

14.30-16.30 Session 5: The future of cancer therapy?

Panel discussion

Moderator: Thierry le Chevalier (Institut Gustave Roussy, France)

Panelists:

- Nils Wilking (Karolinska Institutet, Sweden)
- Helena Brändström (Swedish National Board of Health and Welfare, Sweden)
- Representative from the Melanoma Association (Melanomföreningen, Sweden)
- Yvonne Brandberg (Cancerfonden & Karolinska Institutet, Sweden)
- Ulrik Ringborg (Karolinska University Hospital, Sweden)

16:30

Concluding remarks

